8-K: C4 Therapeutics Appoints Paige Mahaney as Chief Scientific Officer, Stewart Fisher to Retire

C4 Therapeutics has appointed Paige Mahaney as its new Chief Scientific Officer, effective October 28, 2024, following the retirement of Stewart Fisher.

Summary

• C4 Therapeutics announced the appointment of Paige Mahaney as Chief Scientific Officer, effective October 28, 2024.
• The current Chief Scientific Officer, Stewart Fisher, will retire from his role, with his last day being October 28, 2024.
• Dr. Fisher will transition to a Senior Scientific Advisor role until December 31, 2024, and then serve as a consultant through December 31, 2025.
• Dr. Mahaney joins from Exelixis, where she was Senior Vice President and Corporate Head of Drug Discovery.
• Dr. Mahaney's compensation includes a $510,000 annual base salary, a $150,000 sign-on bonus, up to $75,000 for relocation, and a potential 40% performance bonus.
• She will also receive stock options for 345,600 shares and restricted stock units for 76,800 shares, vesting over time.
• Dr. Fisher's departure is not due to any disagreement with the company's operations, policies, or practices.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of a highly qualified new CSO and a well-managed transition plan. The company is clearly investing in its future leadership.

Positives

• The company has successfully recruited a highly experienced Chief Scientific Officer in Paige Mahaney.
• Dr. Mahaney has a strong track record of drug discovery and clinical portfolio development.
• Stewart Fisher will provide continuity and expertise during the transition period as a Senior Scientific Advisor and consultant.
• The company is providing a significant incentive package to attract top talent like Dr. Mahaney.

Negatives

• The departure of Stewart Fisher as Chief Scientific Officer could create a period of transition and potential disruption.
• The company will incur costs associated with Dr. Mahaney's compensation package, including a sign-on bonus and relocation allowance.

Risks

• The transition in leadership could impact the company's research and development efforts.
• There is a risk that Dr. Mahaney's approach may differ from Dr. Fisher's, potentially affecting the company's strategy.
• The company's ability to retain key personnel during the transition period is a risk.

Future Outlook

The company anticipates a smooth transition with Dr. Mahaney taking over as Chief Scientific Officer and Dr. Fisher providing advisory support during the transition period. The company expects to continue its focus on targeted protein degradation and advancing its clinical pipeline.

Management Comments

• Andrew Hirsch, president and chief executive officer of C4 Therapeutics, expressed excitement about welcoming Paige Mahaney and gratitude to Stewart Fisher for his contributions.
• Paige Mahaney stated she was drawn to C4T because of the demonstrated ability of the TORPEDO platform and is thrilled to join the company.

Industry Context

This announcement reflects the ongoing demand for experienced leadership in the biopharmaceutical industry, particularly in the rapidly evolving field of targeted protein degradation. The appointment of Dr. Mahaney, with her extensive experience at Exelixis and Boehringer Ingelheim, highlights the company's commitment to attracting top talent to drive its scientific and clinical programs.

Comparison to Industry Standards

• The compensation package for Dr. Mahaney, including a base salary of $510,000, a sign-on bonus of $150,000, and potential performance bonuses, is competitive with industry standards for Chief Scientific Officers at similar-sized biotech companies.
• Exelixis, where Dr. Mahaney previously worked, is a well-regarded oncology-focused biotech company, and her experience there is a strong positive for C4 Therapeutics.
• Boehringer Ingelheim, another of Dr. Mahaney's previous employers, is a large pharmaceutical company with a strong track record in drug development, further validating her experience.
• The transition plan for Dr. Fisher, including his role as a Senior Scientific Advisor and consultant, is a common practice in the industry to ensure a smooth handover of responsibilities.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CSO positively, potentially impacting the stock price.
• Employees may experience a change in leadership and potential shifts in strategy.
• Customers and partners may see this as a sign of continued investment in research and development.

Next Steps

• Paige Mahaney will assume her role as Chief Scientific Officer on October 28, 2024.
• Stewart Fisher will transition to Senior Scientific Advisor until December 31, 2024, and then to a consultant role until December 31, 2025.
• The company will continue to advance its targeted protein degradation programs.

Key Dates

Keywords

Chief Scientific Officer, Paige Mahaney, Stewart Fisher, retirement, drug discovery, biopharmaceutical, targeted protein degradation, TORPEDO platform, executive appointment, consulting agreement